

## AEGIRBIO ANNOUNCES STRATEGIC NAME CHANGE TO MAGNORAL AB

Lund, 4 May 2024 – AegirBio AB, a pioneer in magnetic test strip technology and saliva diagnostics, announces that it will change its name to MagnOral AB, pending approval at the upcoming Annual General Meeting (AGM) on June 28, 2024.

The decision to rebrand as MagnOral is rooted in a commitment to align the company name with the company's strategic focus. "Magn" reflects the cutting-edge magnetic test strip technology, and "Oral" signifies the dedication to using oral fluid as the primary sample type. By adopting the MagnOral name, the aim is to better communicate the strategic direction and reinforce the brand identity as pioneers in magnetic test strip technology and saliva diagnostics.

"Rebranding to MagnOral will better position us for future growth and success. The name change underscores our forward-looking vision and commitment to innovation in the health sector. The name more accurately reflects our current mission and the innovative solutions we are developing. We believe it will help us better connect with our customers and stakeholders as we continue to advance in the field of health diagnostics," said Marco Witteveen, CEO of AegirBio.

For additional information, please contact: Marco Witteveen, CEO, Aegirbio AB Email: ir@aegirbio.com

## **About AegirBio**

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB; adviser@eminova.se